Povidone iodine/dexamethasone ophthalmic suspension

Drug Profile

Povidone iodine/dexamethasone ophthalmic suspension

Alternative Names: FST-100; PVP-I/dexamethasone; SHP-640

Latest Information Update: 03 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator CLS Pharmaceuticals
  • Developer Shire
  • Class Anti-inflammatories; Antiseptics; Disinfectants
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Infectious conjunctivitis

Most Recent Events

  • 29 Mar 2017 Phase-III clinical trials in Infectious conjunctivitis in USA (Ophthalmic) (NCT03004924)
  • 26 Dec 2016 Shire plans a phase III trial for Adenoviral conjunctivitis (In Infants, In Children, In adolescents, In adults, In elderly) in USA (NCT02998541)
  • 16 Dec 2016 Shire plans a phase III trial for Adenoviral conjunctivitis in USA (Ophthalmic) (NCT02998554)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top